Dopamine and noradrenergic reuptake inhibitors in treatment of s

Details Dopamine and noradrenergic reuptake inhibitors in treatment of s Dopamine and noradrenergic reuptake inhibitors in treatment of s

1992-05-07

1995-09-05

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514327, A61K 31415, A61K 31445

Patent

active

054479487

ABSTRACT:
Mazindol and other dopamine and/or noradrenergic reuptake inhibitors are effective to treat negative symptoms in schizophrenia.

REFERENCES:
patent: 5177081 (1993-01-01), Kaminski
patent: 5190965 (1993-03-01), Ruigt et al.
Delwaide et al., "Mazindol in the Treatment of Parkinson's Disease," Arch. Neurol., vol. 40, pp. 788-790 (Dec. 1983).
Krumholz et al., "Clinical Evaluation of Mazindol in Chronic Schizophrenics," Current Therapeutic Research, vol. 12, No. 9, pp. 609-610 (Sep. 1970).
Joyce et al., Biosis, AN 89:162887, BA87:84988, 1988.
Chinaglia et al., Medline, AN 93063820, 1992.
Hirai et al., Medline, AN 89126127, 1988.

Affiliated with

Also associated with

Rating

Dopamine and noradrenergic reuptake inhibitors in treatment of s does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dopamine and noradrenergic reuptake inhibitors in treatment of s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dopamine and noradrenergic reuptake inhibitors in treatment of s will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-473009